0001062993-24-010183.txt : 20240514
0001062993-24-010183.hdr.sgml : 20240514
20240514163330
ACCESSION NUMBER: 0001062993-24-010183
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240510
FILED AS OF DATE: 20240514
DATE AS OF CHANGE: 20240514
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Van Strydonck, Gerald E.
CENTRAL INDEX KEY: 0001748247
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38624
FILM NUMBER: 24945012
MAIL ADDRESS:
STREET 1: 1895 MOUNT HOPE AVENUE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VACCINEX, INC.
CENTRAL INDEX KEY: 0001205922
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 161603202
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1895 MOUNT HOPE AVE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
BUSINESS PHONE: 585-271-2700
MAIL ADDRESS:
STREET 1: 1895 MOUNT HOPE AVE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
FORMER COMPANY:
FORMER CONFORMED NAME: VACCINEX INC
DATE OF NAME CHANGE: 20021114
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-05-10
0001205922
VACCINEX, INC.
VCNX
0001748247
Van Strydonck, Gerald E.
C/O VACCINEX, INC.
1895 MOUNT HOPE AVENUE
ROCHESTER
NY
14620
1
0
0
0
0
Common Stock
2024-05-10
4
A
0
543
5.75
A
543
D
Stock Option (Right to Buy)
204.0
2027-09-15
Common Stock
426
426
D
Stock Option (Right to Buy)
78.9
2029-03-30
Common Stock
166
166
D
Stock Option (Right to Buy)
116.7
2020-05-15
Common Stock
514
514
D
Stock Option (Right to Buy)
82.8
2029-06-29
Common Stock
159
159
D
Stock Option (Right to Buy)
107.55
2029-09-27
Common Stock
123
123
D
Stock Option (Right to Buy)
72.75
2029-12-28
Common Stock
182
182
D
Stock Option (Right to Buy)
59.25
2021-05-14
Common Stock
1045
1045
D
Stock Option (Right to Buy)
32.25
2022-05-11
Common Stock
1905
1905
D
Stock Option (Right to Buy)
16.8
2023-05-12
Common Stock
3550
3550
D
Stock Option (Right to Buy)
6.15
2024-05-11
Common Stock
9589
9589
D
Stock Option (Right to Buy)
5.75
2024-05-10
4
A
0
10108
0
A
2025-05-10
Common Stock
10108
10108
D
Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these restricted shares in lieu of $3,125 for retainer and meeting fees during the first quarter of 2024.
Exercisable in full as of the date of this report.
This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.
This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.
This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.
This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.
All figures in this Form 4 reflect the Issuer's 1-for-14 reverse stock split effected on February 19, 2024.
/s/ Maurice Zauderer, Attorney-in-Fact for Gerald E. Van Strydonck
2024-05-14